Author:
Ferretti Francesca,Cannatelli Rosanna,Benucci Maurizio,Carmagnola Stefania,Clementi Emilio,Danelli Piergiorgio,Dilillo Dario,Fiorina Paolo,Galli Massimo,Gallieni Maurizio,Genovese Giovanni,Giorgi Valeria,Invernizzi Alessandro,Maconi Giovanni,Maier Jeanette A.,Marzano Angelo V.,Morpurgo Paola S.,Nebuloni Manuela,Radovanovic Dejan,Riva Agostino,Rizzardini Giuliano,Sabiu Gianmarco,Santus Pierachille,Staurenghi Giovanni,Zuccotti Gianvincenzo,Sarzi-Puttini Pier Carlo,Ardizzone Sandro
Abstract
Since March 2020, the outbreak of Sars-CoV-2 pandemic has changed medical practice and daily routine around the world. Huge efforts from pharmacological industries have led to the development of COVID-19 vaccines. In particular two mRNA vaccines, namely the BNT162b2 (Pfizer-BioNTech) and the mRNA-1273 (Moderna), and a viral-vectored vaccine, i.e. ChAdOx1 nCoV-19 (AstraZeneca), have recently been approved in Europe. Clinical trials on these vaccines have been published on the general population showing a high efficacy with minor adverse events. However, specific data about the efficacy and safety of these vaccines in patients with immune-mediated inflammatory diseases (IMIDs) are still lacking. Moreover, the limited availability of these vaccines requires prioritizing some vulnerable categories of patients compared to others. In this position paper, we propose the point of view about the management of COVID-19 vaccination from Italian experts on IMIDs and the identification of high-risk groups according to the different diseases and their chronic therapy.
Subject
Immunology,Immunology and Allergy
Reference131 articles.
1. Pfizer-BioNTech COVID-19 VaccineEmergency Use Authorization Review Memorandum,2020
2. Moderna COVID-19 VaccineEmergency Use Authorization Review Memorandum,2020
3. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine;Polack;N Engl J Med,2020
4. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine;Baden;N Engl J Med,2020